Results for:(48 found)
Dec 31, 2012 3:07PM on Top StocksBy John Reese

Fearing the fiscal cliff-associated tax hikes, many investors have been dumping dividend stocks. They may have been making a big mistake.

Dec 13, 2012 2:17PM on Top StocksBy MSN Money Partner

Stocks are lower, extending the slide that began late Wednesday following Ben Bernanke's press conference.

Dec 13, 2012 1:12PM on Top StocksBy InvestorPlace

Some pharma stocks could get a shot in the arm as CDC issues early warning.

Nov 13, 2012 12:27PM on Top StocksBy TheStreet Staff

The Big Pharma company and its partner Nektar added data to a phase III study of naloxegol that could have improperly changed results.

Oct 31, 2012 10:38AM on Top StocksBy InvestorPlace

The revenue in question seems too small to make a difference.

Sep 21, 2012 10:34AM on Top StocksBy TheStockAdvisors

The drug company is a defensive, income generator with added potential for capital gains.

Tags: AZNBMY
Sep 19, 2012 11:01AM on Top StocksBy MSN Money Partner

GlaxoSmithKline is downgraded to 'underperform,' while AstraZeneca is upgraded to 'neutral.'

Sep 10, 2012 11:18AM on Top StocksBy MSN Money Partner

Sprint is upgraded to 'buy,' and Celgene is downgraded to 'neutral.'

VIDEO ON MSN MONEY

DATA PROVIDERS

Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.

TOP STOCKS

More

MARKET DISPATCHES

No more Dispatches; here's where to find market news

The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.

More